Tracy A. Glauser, MD, is director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center and professor of pediatrics in the University of Cincinnati College of Medicine. Dr. Glauser received his medical degree, cum laude, from Jefferson Medical College in Philadelphia, PA. He completed his residency in pediatrics at the John Hopkins Hospital in Baltimore, MD, and fellowship in child neurology at The Children’s Hospital of Philadelphia, University of Pennsylvania in Philadelphia, PA. Dr. Glauser completed a National Institute of Neurological Disorders and Stroke research fellowship in pediatric neurology and was a fellow in epilepsy and electroencephalography at St. Louis Children’s Hospital, Washington University School of Medicine in St. Louis, Missouri.
Dr. Glauser has authored and co-authored more than 130 articles and book chapters, been involved with the development of six evidence-based guidelines about epilepsy therapy and given over 150 invited lectures throughout the world. He has been the principal investigator on multiple NIH grants. Currently, Dr. Glauser directs the NIH funded Childhood Absence Epilepsy clinical trial involving 32 pediatric centers around the United States. Dr. Glauser’s fields of expertise are pediatric neurology, pediatric epilepsy, clinical pharmacology and pharmacogenetics.
MD: Jefferson Medical College, Philadelphia, PA, 1985.
Residency: Johns Hopkins Hospital, Baltimore, MD.
Fellowship: St. Louis Children's Hospital, St. Louis, MO.
Certification: Pediatrics, 1990; Neurology (with special competence in child neurology), 1991.
Epilepsy; pharmacogenetics; clinical pharmacology
Clinical pharmacology; pharmacogenetics; antiepileptic clinical trials
Neurology, Clinical Pharmacology, Genomics
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Development of information sharing in language neocortex in childhood-onset drug-resistant epilepsy. Epilepsia. 2019; 60:393-405.
Pretreatment behavior and subsequent medication effects in childhood absence epilepsy. Neurology. 2017; 89:1698-1706.
Pretreatment seizure semiology in childhood absence epilepsy. Neurology. 2017; 89:673-679.
Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Annals of Neurology. 2017; 81:444-453.
Second monotherapy in childhood absence epilepsy. Neurology. 2017; 88:182-190.
Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial. Neurology. 2015; 85:1108-1114.
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. The New England journal of medicine. 2010; 362:790-799.
Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy. Clinical Pharmacology and Therapeutics. 2023; 114:459-469.
Early Clinical Variables Associated With Refractory Convulsive Status Epilepticus in Children. Neurology. 2023; 101:e546-e557.
Tracy A. Glauser, MD, Michael T. Sorter, MD ...5/30/2023
Tracy A. Glauser, MD, John P. Pestian, PhD, MBA11/8/2021
Tracy A. Glauser, MD, John P. Pestian, PhD, MBA ...2/10/2021
Tracy A. Glauser, MD, Nathan Pajor, MD ...11/23/2020
Tracy A. Glauser, MD9/5/2019